Fatty liver disease, now officially called MASLD, is shockingly common. It affects about one in three adults globally. It happens when too much fat builds up in the liver.
Often, it causes no symptoms. But for up to a third of those affected, the fat causes inflammation and injury. This leads to fibrosis—tough scar tissue that replaces healthy liver cells.
If fibrosis gets worse, it can progress to severe cirrhosis or liver cancer. It can mean needing a liver transplant. For decades, once that scarring process started, the medical goal was just to try to slow it down.
The Surprising Shift
The old thinking was that liver scarring was mostly a one-way street. The new goal is not just to stop it, but to reverse it.
A massive new analysis, published in the European Journal of Gastroenterology & Hepatology, has combed through data from over 10,000 patients. It compared 48 different clinical trials. The goal was simple: which drugs actually help the liver heal its own scars?
The answer provides a new map for treatment.
Think of your liver like a busy factory town. When it’s healthy, everything runs smoothly. With fatty liver disease, it’s like a toxic spill causes damage. The town’s repair crews (called fibroblasts) go into overdrive. They lay down too much concrete (scar tissue) everywhere, blocking the streets.
The most promising new drugs act like expert cleanup supervisors. They are based on a natural hormone in your body called FGF21.
These drug versions of FGF21 tell the overactive repair crews to calm down. They help clear out the toxic fat causing the damage. They also encourage the body to break down the excess “concrete” or scar tissue. This allows the normal liver “streets” to open up again.
The researchers looked at two key things. First, they checked if drugs improved the actual stage of fibrosis on a liver biopsy. This is the gold standard test. Second, they looked at non-invasive scans that measure liver stiffness, a proxy for scarring.
The results were clear. For reducing fibrosis stage, three drugs stood out: pegozafermin, obeticholic acid (OCA), and resmetirom. They all performed better than a placebo (a dummy pill).
For improving liver stiffness on a quick scan, pegozafermin was the clear leader.
But Here's the Catch
This doesn’t mean these treatments are available at your pharmacy yet.
The analysis ranked pegozafermin and a similar drug, pegbelfermin, as the most effective for fibrosis improvement. These are FGF21-based drugs. They are still in the final phases of clinical testing.
Obeticholic acid (OCA) is further along. It is already approved for a different, rarer liver disease. But its use for common fatty liver disease is not yet approved in the U.S. and is under strict review due to potential side effects.
Resmetirom is in a unique spot. It was recently approved for MASH (the inflammatory form of fatty liver) with significant fibrosis. This analysis adds to the evidence for its use.
This research is a signpost for the future, not a current prescription. If you have been diagnosed with fatty liver disease and are worried about fibrosis, talk to your doctor.
Ask about your fibrosis stage. It can be assessed through blood tests, special scans, or sometimes a biopsy. The most important action you can take today is still the foundation: work with your healthcare team on sustainable lifestyle changes.
These new drugs, when and if approved, will likely be tools used alongside these lifestyle efforts, not replacements for them.
Understanding the Limits
This was a network meta-analysis. It’s a powerful way to compare many drugs at once, but it has limits. It indirectly compares trials that were done separately. The studies included had different designs and patient types.
Also, the follow-up time in most trials was relatively short—often just about a year. We need to see if this scar improvement lasts for many years and truly prevents bad outcomes like liver failure.
The path is now clearer. The most promising drugs targeting the FGF21 pathway are moving into larger, longer Phase III trials. These final-stage trials will confirm their safety and just how much benefit they provide in the real world.
Regulatory agencies like the FDA will then review that data for approval. This process takes time, often several years. But for the first time, there is a growing pipeline of potential medicines aimed directly at healing the scarred liver. The message is shifting from managing decline to enabling repair.
